Esperion Therapeutics | ESPR - Net Income


Esperion Therapeutics reported $61.83M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Alterity Therapeutics Limited AUD -5.77M 2.26M Jun/2023
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cipla INR 6.76B 6.75B Dec/2025
CSL USD 401M 96.5M Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Geron USD -31.14M 12.72M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024